Comparison of human peripheral blood dendritic cell activation by four fucoidans

Zhang, Wei; Park, Hae‐Bin; Yadav, Dhananjay; Hwang, Juyoung; An, Eun‐Koung; Eom, Hee-Yun; Kim, Sojung; Kwak, Minseok; Lee, Peter Chang-Whan

doi:10.1016/j.ijbiomac.2021.01.155

Cited by 19 publications

(15 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The weight-average molecular weight of ECF was approximately 42.95 kDa and polydispersity index (PDI) was 1.39 as homogeneity (Table 1). The monosaccharide composition of ECF determined that the major sugar was fucose (45.13%) and galactose (23.24%), whereas xylose (1.78%), glucose (1.37%), and mannose (0.55%) contents constituted a minor component, which was consistent with previous studies [20,41]. Furthermore, Fourier-transform infrared spectroscopy (FT-IR) spectral peaks of ECF revealed that the presence of sulfate groups at 823.51 cm −1 for C-O-S and at 1217.82 cm −1 for S=O (Figure S1).…”

Section: Chemical Analysis Of Ecfsupporting

confidence: 92%

“…A previous study showed that fucoidan from Ecklonia cava (ECF) also induces activation of immune cells [19]. Our group has also shown that ECF contained a higher amount of fucose, galactose and sulfate ester group than Macrocystis pyrifera fucodian, Undaria pinnatifida fucoidan and Fucus vesiculosus fucoidan [18] and it promotes the strongest effect of immune cell activation compared to those fucoidans in human peripheral blood mononuclear cells [20]. In addition, intraperitoneal administration with ECF activates splenic DCs in the mouse in vivo, which elicits antigen-specific immune responses by the ECF and ovalbumin in the mice [7].…”

Section: Introductionmentioning

confidence: 77%

“…Seaweed fucoidans have been explored for their mechanistic activities of immunomodulation; F. vesiculosus-extracted fucoidan induces DC activation in mice and humans, thereby enhancing T cell immunity, which further induces anti-tumor immunity [6,17]. Fucoidans contain various types of monosaccharides such as fucose, xylose, mannose, glucose, and galactose [17,20]. In our previous study, the ECF adjuvant effect in combination with a carcinoma self-antigen has been explored, which protects mice from developing B16 melanoma [41].…”

Section: Discussionmentioning

confidence: 99%

“…Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are well known as the main contributors to cancer immunotherapy [24][25][26][27]. The stimulation of these CTLs and NK cells is mediated by antigen-presenting cells, especially DCs [20,28]. Mucosal surfaces covered by mucus are physical barriers that inhibit vaccines and adjuvants from reaching mucosal epithelial cells, thereby blocking immune responses of antigen-presenting cells (APCs) [29,30].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer

Zhang

Hwang

Yadav

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

Although fucoidan, a well-studied seaweed-extracted polysaccharide, has shown immune stimulatory effects that elicit anticancer immunity, mucosal adjuvant effects via intranasal administration have not been studied. In this study, the effect of Ecklonia cava-extracted fucoidan (ECF) on the induction of anti-cancer immunity in the lung was examined by intranasal administration. In C57BL/6 and BALB/c mice, intranasal administration of ECF promoted the activation of dendritic cells (DCs), natural killer (NK) cells, and T cells in the mediastinal lymph node (mLN). The ECF-induced NK and T cell activation was mediated by DCs. In addition, intranasal injection with ECF enhanced the anti-PD-L1 antibody-mediated anti-cancer activities against B16 melanoma and CT-26 carcinoma tumor growth in the lungs, which were required cytotoxic T lymphocytes and NK cells. Thus, these data demonstrated that ECF functioned as a mucosal adjuvant that enhanced the immunotherapeutic effect of immune checkpoint inhibitors against metastatic lung cancer.

show abstract

Section: Chemical Analysis Of Ecfsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer

Zhang

Hwang

Yadav

et al. 2021

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Meanwhile, mice could endure a repeated dosage of 10 mg/kg of fucoidan, and the drug revealed remarkable antitumor (inhibited tumor growth by 33%) and antimetastatic activities (29% reduction) [ 24 ]. Intraperitoneal injection and/or administration of fucoidan through food, gavages, subcutaneous injection, and intravenous injection have also been thoroughly researched [ 25 , 26 , 27 , 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles

et al. 2021

Self Cite

View full text Add to dashboard Cite

Several types of cancers share cellular and molecular behaviors. Although many chemotherapy drugs have been designed to weaken the defenses of cancer cells, these drugs may also have cytotoxic effects on healthy tissues. Fucoidan, a sulfated fucose-based polysaccharide from brown algae, has gained much attention as an antitumor drug owing to its anticancer effects against multiple cancer types. Among the anticancer mechanisms of fucoidan are cell cycle arrest, apoptosis evocation, and stimulation of cytotoxic natural killer cells and macrophages. Fucoidan also protects against toxicity associated with chemotherapeutic drugs and radiation-induced damage. The synergistic effect of fucoidan with existing anticancer drugs has prompted researchers to explore its therapeutic potential. This review compiles the mechanisms through which fucoidan slows tumor growth, kills cancer cells, and interacts with cancer chemotherapy drugs. The obstacles involved in developing fucoidan as an anticancer agent are also discussed in this review.

show abstract

Artificial Immunogenic Cell Death Lipid Nanoparticle Functions as a Therapeutic Vaccine for Cancer

Kim

Park

et al. 2023

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Anticancer drug-mediated induction of immunogenic cell death (ICD) blocks metastasis or recurrence in cancer cells by promoting specific immune activity against cancer antigens. However, this strategy has failed to afford adequate treatment efficiency. Overcoming the failure of ICD-mediated cancer therapy, lipid nanoparticles (LNPs) containing cancer cell surface proteins are synthesized using sonication and extrusion without microfluidics. In addition, these LNPs are decorated with high-mobility group box 1 protein and calreticulin, indicators of ICD, and named artificial ICD LNPs (AiLNPs). Administration of AiLNPs effectively targets dendritic cells (DCs) and induces DC activation in mice. Moreover, treating CT-26 tumor-bearing mice with AiLNPs inhibits tumor growth by inducing CT-26 antigen-specific T-cell immunity. Furthermore, AiLNPs containing Lewis lung carcinoma (LLC1) membrane proteins can prevent metastatic LLC1 tumor growth in the lung via LLC1 antigen-specific T-cell activation. Finally, AiLNPs synthesized with human breast cancer membrane proteins activate DC-mediated antigenspecific T-cell immunity, effectively killing tumor cells. Therefore, AiLNPs are expected to be developed as a patient-specific cancer treatment to prevent cancer recurrence and metastasis.

show abstract

Comparison of human peripheral blood dendritic cell activation by four fucoidans

Cited by 19 publications

References 52 publications

Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer

Enhancement of Immune Checkpoint Inhibitor-Mediated Anti-Cancer Immunity by Intranasal Treatment of Ecklonia cava Fucoidan against Metastatic Lung Cancer

The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles

Artificial Immunogenic Cell Death Lipid Nanoparticle Functions as a Therapeutic Vaccine for Cancer

Contact Info

Product

Resources

About